- Home
- WRN vs OVID Comparison
WRN vs OVID Comparison
Compare WRN & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRN | OVID |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.2M | 562.5M |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WRN | OVID |
|---|---|---|
| Price | $2.54 | $2.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.58 | ★ $4.60 |
| AVG Volume (30 Days) | 901.6K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $1.53 | $1.12 |
| 52 Week High | $4.26 | $3.11 |
Technical Indicators
Market Signals| Indicator | WRN | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 51.78 |
| Support Level | $2.28 | $2.60 |
| Resistance Level | $2.61 | $2.77 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 80.00 | 35.48 |
Price Performance
Historical ComparisonAbout WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.